1374856-34-4 Usage
General Description
(E)-ethyl 3-(4-(difluoromethoxy)phenyl)acrylate is a chemical compound with the molecular formula C12H12F2O3. It is an ester of acrylate that is used in the production of various industrial and consumer products. (E)-ethyl 3-(4-(difluoromethoxy)phenyl)acrylate is a clear, colorless liquid that is insoluble in water but soluble in organic solvents. It is used as a building block in the synthesis of pharmaceuticals, agrochemicals, and functional materials. Additionally, (E)-ethyl 3-(4-(difluoromethoxy)phenyl)acrylate is also used as a starting material for the production of polymers and coatings. Its unique chemical structure and properties make it a versatile compound with a wide range of potential applications.
Check Digit Verification of cas no
The CAS Registry Mumber 1374856-34-4 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,3,7,4,8,5 and 6 respectively; the second part has 2 digits, 3 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 1374856-34:
(9*1)+(8*3)+(7*7)+(6*4)+(5*8)+(4*5)+(3*6)+(2*3)+(1*4)=194
194 % 10 = 4
So 1374856-34-4 is a valid CAS Registry Number.
1374856-34-4Relevant articles and documents
Design and optimization of quinazoline derivatives as melanin concentrating hormone receptor 1 (MCHR1) antagonists: Part 2
Sasmal, Sanjita,Balasubrahmanyam,Kanna Reddy, Hariprasada R.,Balaji, Gade,Srinivas, Gujjary,Cheera, Srisailam,Abbineni, Chandrasekhar,Sasmal, Pradip K.,Khanna, Ish,Sebastian,Jadhav, Vikram P.,Singh, Manvendra P.,Talwar, Rashmi,Suresh,Shashikumar, Dhanya,Harinder Reddy,Sihorkar,Frimurer, Thomas M.,Rist, ?ystein,Elster, Lisbeth,H?gberg, Thomas
scheme or table, p. 3163 - 3167 (2012/06/04)
Melanin concentrating hormone receptor 1 (MCHR1) antagonists have potential for the treatment of obesity and several CNS disorders. In the preceding article, we have described a novel series of quinazolines as MCHR1 antagonists and demonstrated in vivo proof of principle with an early lead. Herein we describe the detailed SAR and SPR studies to identify an optimized lead candidate having good efficacy in a sub-chronic DIO model with a good cardiovascular safety window.
